With abstracts presaging the customary avalanche of data due from the American Society of Clinical Oncology (ASCO) meeting next month, the mechanism of KRAS inhibition caused an expectedly large share of talk, though efforts remain far from mature, and too fresh for big conclusions. Read More
DUBLIN – Morphosys AG took a significant step toward realizing its ambition to begin marketing its first product by mid-next year, as its CD19-directed antibody, tafasitamab (MOR-208), hit the primary endpoint of a pivotal phase II trial in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
Passion, politics and prices were all on display Thursday as the House Oversight and Reform Committee attempted to delve into the pricing of Gilead Sciences Inc.'s Truvada, which is used to both treat and prevent HIV. Read More
Following the successful progress of gene therapies in treating rare disease, they are now beginning to be applied to CNS disorders, including Parkinson's and Alzheimer's disease, and other serious conditions. Drug delivery to the brain has long been a challenge, and a great deal of research is being focused on identifying various strategies that are able to ferry medicines across the blood-brain barrier (BBB), which typically blocks the transport of molecules and particles into the brain, and effectively deliver their therapeutic payloads. In this two-part feature, the progress being made in the field will be explored. Read More
Parvus Therapeutics Inc. and Genentech Inc. have agreed to develop, manufacture and commercialize Parvus' therapeutics to treat inflammatory bowel, autoimmune liver and celiac diseases. The platform gets the job done without immunosuppression, a singular approach and technology. Read More
HONG KONG - Pharmaceutical manufacturer Huons Co. Ltd. and biopharmaceutical research and development venture Genexine Inc. inked a memorandum of understanding for a deal, under which they will combine Genexine's biobetters and rare disease pipeline with Huons' existing global commercial network. Read More
TEL AVIV, Israel – An awakening is underway in the biotech field to develop new products from cannabis, with efforts based on strong science and supported by clinical trials and rigorous research, particularly into the many potential uses of cannabinoids. Read More
HONG KONG – The Korea Cancer Biomarker Consortium (KCBC), a research group of 13 university hospitals in South Korea, and South Korean biotech Cbsbioscience Inc. inked a deal with medical research institutes in Italy and Japan to develop biomarkers aimed at improving the efficiency of cancer drugs. Read More
Dogma Therapeutics LLC, of Cambridge, Mass., disclosed an oral PCSK9 inhibitor program. In dyslipidemic nonhuman primates, multiple Dogma inhibitors produced significant and robust lowering of LDL cholesterol following multiple weeks of administration. Read More
Hemostemix Inc., of Calgary, Alberta, said it has concluded a first closing of the $1 million nonbrokered private placement of convertible debentures, and issued debentures in the amount of $525,000. The net proceeds will be used to continue to fund the company's phase II trial for critical limb ischemia and for general working capital. Read More
